본문 바로가기
KERD
논문KCI 등재

비소세포폐암에 사용되는 항암화학요법의 요양급여기준 적절성 평가

Assessment of appropriateness of standard for insurance coverage on chemotherapy used in non-small cell lung cancer (NSCLC)

박은지|배민경|윤정현|김정연
한국임상약학회 (Korean College Of Clinical Pharmacy)|2011.10|한국임상약학회지 (Korean Journal of Clinical Pharmacy)|제21권 제3호|pp. 193-207

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

chemotherapytargeted therapynon-small cell lung cancer (NSCLC)
주제분류약학

초록

Purpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations. Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed. Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence. Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance,despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences. Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.

Abstract

Purpose: The purpose of this study is to assess appropriateness of current standard for insurance coverage by Health Insurance Review & Assessment Service (HIRA) on chemotherapy used in the treatment of advanced non-small cell lung cancer (NSCLC), by reviewing a variety of clinical evidences, and thereby, if needed, to propose an updated evidence-based recommendations. Methods: We collected data from HIRA regarding on the insurance standard which includes the scope and conditions for coverage on systemic chemotherapy of NSCLC. We performed a search for clinical databases and examined the most current clinical evidence from clinical literature including various clinical practice guidelines. Based on the collected data the appropriateness of HIRA standard for insurance coverage of chemotherapy of NSCLC was assessed. Results: Collected data demonstrated that HIRA standard did not reflect the most current clinical practice and evidence. Some were inappropriately listed in HIRA formulary and accepted as a chemotherapy being covered by insurance,despite the lack of evidences of clinical efficacy or superiority over other chemotherapeutic agents or regimens. In addition, there seems to be a need for a modification on the standard for insurance coverage of certain newer chemotherapeutic agents based on the current accumulated data showing their clinical efficacy and benefits in the selected group of NSCLC patients. Therefore, we concluded that current HIRA standard for insurance coverage on chemotherapy of NSCLC needs to be revised and we proposed an updated recommendation based on these latest clinical evidences. Conclusion: The standard for insurance coverage of chemotherapy should be continually examined its appropriateness based on the most recent clinical evidences in a timely manner so as to provide the most effective and safe therapy to cancer patients.

참고문헌 (100)

  1. "GLOBOCAN 2008. Cancer incidence and mortality worldwide in 2008"[URL]
  2. Jemal A, "Cancer statistics 2010", CA Cancer J Clin, 60, pp.277~300 (2010)
  3. "Cancer Statistics"[URL]
  4. WHO, "Pathology and genetics of tumours of the lung, pleura, thymus and heart" (2004), IARC Press
  5. In KH, "Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry Study", LUNG CANCER, 64(2), pp.232~237 (2009), Elsevier Scientific Publishers
  6. D'Addario G, "Metastatic nonsmall- cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 21, pp.v116~v119 (2010)
  7. "항암화학요 법 등 공고내용 전문"[URL]
  8. "대한폐암 학회 진료지침. 2nd edition"[URL]
  10. Azzoli CG, "American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer", J Clin Oncol, 27, pp.6251~6266 (2009)
  11. Alberts WM, "Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition)", Chest, 132, pp.1S~19S (2007)
  12. Lilenbaum RC, "Singleagent versus combination chemotherapy in advanced nonsmall- cell lung cancer: The Cancer and Leukemia Group B (study 9730)", J Clin Oncol, 23, pp.190~196 (2005)
  13. Delbaldo C, "Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis", JAMA, 292, pp.470~484 (2004)
  14. Georgoulias V, "Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial", J Clin Oncol, 22, pp.2602~2609 (2004)
  15. Negoro S, "Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer", Br J Cancer, 88, pp.335~341 (2003)
  16. Sederholm C, "Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group", J Clin Oncol, 23, pp.8380~8388 (2005)
  17. D'Addario G, "Platinum-based versus non-platinum-based chemotherapy in advanced nonsmall- cell lung cancer: A meta-analysis of the published literature", J Clin Oncol, 23, pp.2926~2936 (2005)
  18. Hotta K, "Addition of platinum compounds to a new agent in patients with advanced nonsmall- cell lung cancer: A literature based meta-analysis of randomised trials", Ann Oncol, 15, pp.1782~1789 (2004)
  19. Pujol JL, "Should chemotherapy combinations for advanced non-small-cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials", Lung Cancer, 51, pp.335~345 (2006)
  20. Rajeswaran A, "Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small-cell lung carcinoma: A systematic review of randomized controlled trials", Lung Cancer, 59, pp.1~11 (2008)
  21. Hotta K, "Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer", Lung Cancer, 57, pp.348~358 (2007)
  22. Ardizzoni A, "Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis", J Natl Cancer Inst, 99, pp.847~857 (2007)
  23. Rosell R, "Phase III randomized trial comparing paclitaxel", carboplatin with paclitaxel, Ann Oncol, pp.2002, 13[DOI]
  24. Schiller JH, "Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
  25. Scagliotti GV, "Phase III randomized trial comparing three platinum-based doultets in advanced non-small-cell lung cancer", J Clin Oncol, 20, pp.4285~4291 (2002)
  26. Ohe Y, "Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four- Arm Coopertaive Study in Japan", Ann Oncol, 18, pp.317~323 (2007)
  27. Alberola V, "Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial", J Clin Oncol, 21, pp.3207~3213 (2003)
  28. Comella P, "Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: A phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)", Ann Oncol, 18, pp.324~330 (2007)
  29. Greco FA, "Paclitaxel", carboplatin, vinorelbine in advanced non-small-cell lung cancer: A phase II, pp.III study of the Minnie Pearl Cancer Research Network, Clin Lung Cancer[DOI]
  30. Gullick WJ, "Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers", Br Med Bull, 47, pp.87~98 (1991)
  31. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
  32. Parez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
  33. Mok TS, "Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
  34. Yang CH, "Final overall survival (OS) results from a phase III, randomised, openlabel, first-line study of gefinitib (G) v carboplatin", paclitaxel (C, Ann Oncol, pp.2010, 21(8)[DOI]
  35. Mitsudomi T, "Gefinitib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
  36. Keedy VL, "American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy", J Clin Oncol, 29, pp.2121~2127 (2011)
  37. Pao W, "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain", PLoS Med, 2, pp.e73~ (2005)
  38. Sandler A, "Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer", N Engl J Med, 355, pp.2542~2550 (2006)
  39. Forbes SA, "The catalogue of somatic mutations in cancer (COSMIC)", Curr Protoc hum Genet, (chapter 10) (2008)
  40. Eberhard DA, "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib", J Clin Oncol, 23, pp.5900~5909 (2005)
  41. Miller VA, "Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib", J Clin Oncol, 26, pp.1472~1478 (2008)
  42. Choi YL, "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors", N Engl J Med, 363, pp.1734~1739 (2010)
  43. Forbes SA, "The catalogue of somatic mutations in cancer (COSMIC)", Curr Protoc Hum Genet, (chapter 10) (2008)
  44. Eberhard DA, "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall- cell lung cancer treated with chemotherapy alone and in combination with erlotinib", J Clin Oncol, 23, pp.5900~5909 (2005)
  45. Miller VA, "Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib", J Clin Oncol, 26, pp.1472~1478 (2008)
  46. Choi YL, "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors", N Engl J Med, 363, pp.1734~1739 (2010)
  47. Pao W, "New driver mutations in non-small-cell lung cancer", Lancet Oncol, 12, pp.175~180 (2011)
  48. Christensen JG, "Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma", Mol Cancer Ther, 6, pp.3314~3322 (2007)
  49. Kwak EL, "Anaplastic Lymphoma Kinase Inhibition in non-samll-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
  50. Gridelli C, "Second-line treatment of advanced non-small cell lung cancer", J Thorac Oncol, 3, pp.430~440 (2008)
  51. Di Maio M, "Meta-analysis of single-agent chmeotherapy compared with combination chemotherapy as second-line treatment of advnaced nonsmall- cell lung cancer", J Clin Oncol, 27, pp.1836~1843 (2009)
  52. Bang Y, "Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small-cell cancer (NSCLC)", J Clin Oncol, 28, pp.18s~ (2010)
  53. Scagliotti GV, "Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer", J Clin Oncol, 26, pp.3543~3551 (2008)
  54. Thatcher N, "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)", Lancet, 366, pp.1527~1537 (2005)
  55. Lee DH, "Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy", Clin. Cancer Res., 16(4), pp.1307~1314 (2010)
  56. Gullen MH, "Mitomycin, ifosfamide, and cisplatin in unresectable nonsmall- cell lung cancer; effects on survival and quality of lif", J Clin Oncol, 17, pp.3188~3194 (1999)
  57. Spiro S, "Chemotherapy versus supportive care in advanced non-small-cell lung cancer; improved survival without detriment to quality of life", Thorax, 59, pp.828~836 (2004)
  58. Crino L, "Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomised trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)", Ann Oncol, 6, pp.342~353 (1995)
  59. Danson S, "Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine and cisplatin in patients with advanced nonsmall cell lung carcinoma", Cancer, 98, pp.542~553 (2003)
  60. Booton R, "A phase III trial of docetaxel", carboplatin versus mitomycin C, cisplatin (MIC) or mitomycin C, pp.vinblastine, cisplatin (MVP) in patients with advnaced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)[DOI]
  61. Scagliotti GV, "Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer", J Natl Cancer inst, 95, pp.1453~1461 (2003)
  62. Song SY, "Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer", Jpn J Clin Oncol, 33, pp.509~513 (2003)
  63. Montalar J, "Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer", Lung Cancer, 34, pp.305~311 (2001)
  64. Souquet PJ, "GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small lung cancer patients", Ann Oncol, 13, pp.1853~1861 (2002)
  65. Zhao Y, "Comparative study on gemcitabine plus cisplatin and vinorelbine plus ifosfamide plus cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer", Zhongguo Fei AiZa Zhi, 7, pp.449~451 (2004)
  66. Young Chul Kim, "Effect of Vinorelbine, Ifosfamide and Cisplatin Combination Chemotherapy in Stage III-IV Non-Small-Cell Lung Cancer", Cancer Research and Treatment, 34(5), pp.352~356 (2002), 대한암학회
  67. Cuomo AM, "Three conventional-drug combination (ifosfamide, carboplatin, etoposide-ICE regimen) in advanced non-small cell lung cancer (NSCLC)", J Chemother, 13, pp.434~439 (2001)
  68. Preti P, "Phase II study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non small cell lung cancer (NSCLC)", J Chemother, 10, pp.492~495 (1998)
  69. Hsieh RK, "Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer", Am J Clin Oncol, 17, pp.509~513 (1994)
  70. Li Dx, "Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and arboplatin regimen for treatment of patients with advanced non-small cell lung cancer", Ai Zheng, 21, pp.412~415 (2002)
  71. 이구, "진행성 비소세포 폐암 환자에서 Ifosfamide, Cisplatin, Etoposide(ICE) 복합화학요법의 효과", Tuberculosis and Respiratory Diseases, 52(4), pp.309~316 (2002), 대한결핵및호흡기학회
  72. Shepherd FA, "Ifosfamide, cisplatin, and etoposide(ICE) in the treatment of advanced non-small cell lung cancer", Semin Oncol, 19(1), pp.54~58 (1992)
  73. Shirinian M, "Phase II study of cisplatin, ifosfamide with mesna and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer", Semin Oncol, 19(1), pp.49~53 (1992)
  74. Feld R, "Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. An LCSG Trial", Chest, 106, pp.307S~309S (1994)
  75. Hanna N, "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy", J Clin Oncol, 22, pp.1589~1597 (2004)
  76. 김주항, "Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study", Lancet, 374(9699), pp.1432~1440
  77. Clarke SJ, "Phase II trial of pemetrexed disodium in chemotherapy-naive patients with advanced non small cell lung cancer", Ann Oncol, 13, pp.737~741 (2002)
  78. Rusthoven JJ, "Multitargeted antifolate LY231114 as first line chemotherapy for patients with advanced non small cell lung cancer: phase II study", J Clin Oncol, 17, pp.1194~1199 (1999)
  79. Lee HY, "Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial", LUNG CANCER, 66, pp.338~343 (2009), Elsevier Scientific Publishers
  80. Gridelli C, "Single-agent pemetrexed or sequential pemetrexed", gemcitabine as frontline treatment of advanced NSCLC in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phaseⅡ trial, 2007, pp.2, 221~229
  81. "심폐병리연 구회 폐암환자 1천700여명 분석결과"[URL]
  82. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
  83. Zhou C, "Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-smallcell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations", Ann Oncol, 21(8) (2010)
  84. Lee S, "TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapynaive patient switch advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy", J Clin Oncol, 28, pp.540s~ (2010)
  85. Kim ST, "Comparison of gefinitib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy", Cancer, 116, pp.25~33 (2010)
  86. 이진화, "진행성 비소세포폐암 환자에서 Gefitinib와 Erlotinib의 비교", Tuberculosis and Respiratory Diseases, 66(4), pp.280~287 (2009), 대한결핵및호흡기학회
  87. 문대성, "여성 폐암 환자에서 Gefitinib과 Erlotinib 치료 성적 비교", 대한내과학회지, 76(2), pp.179~185 (2009), 대한내과학회
  88. 배나래, "비소세포폐암 환자에 있어서 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors의 약효 및 rash 발생과 관련한 인자에 대한 연구", 한국임상약학회지, 18(2), pp.75~83 (2008), 한국임상약학회
  89. Chen YM, "First-line systemic therapy for metastatic non-small-cell lung cancer-A review", J Exp Clin Med, 3, pp.116~120 (2011)
  90. Akerley W, "A Phase II study of erlotinib as inital treatment for patients with stage IIIB-IV non-small cell lung cancer", J Thorac Oncol, 4, pp.214~219 (2009)
  91. Xu XH, "Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small lung cancer", Cancer Chemother Pharmacol, 67, pp.478~479 (2011)
  92. 노재경, "Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial", Lancet, 373(9674), pp.1525~1531
  93. Lin H, "Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and metaanalysis", Lung Cancer, 70, pp.57~62 (2010)
  94. 조병철, "The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer", Yonsei Medical Journal, 51(1), pp.1~8 (2010), 연세대학교대학
  95. Tsao AS, "Cetuximab combined with chemotherapy in nonsmall cell lung cancer", Community Oncol, 7, pp.17~22 (2010)
  96. Belani CP, "Randomized phase III trial comparing cisplatin-etoposide to carboplatinpaclitaxel in advanced or metastatic non-small cell lung cancer", Ann Oncol, 16, pp.1069~1075 (2005)
  97. Itri LM, "A review of etoposide in patients with non-small-cell lung cancer (NSCLC)", Cancer Treat Rev, 9, pp.115~118 (1982)
  98. Kakolyris S, "Treatment of non-small-cell lung cancer with prolonged oral etoposide", Am J Clin Concol, 21, pp.505~508 (1998)
  99. Sorio R, "Oral etoposide in elderly patients with advanced non small cell lung cancer: a clinical and pharmacological study", J Chemother, 18, pp.188~191 (2006)
  100. Kim YH, "Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer", Respir Med, 104, pp.434~439 (2010)

관련 논문AI추천

신세포암에 사용되는 전신 항암요법의 요양급여기준에 관한 고찰김정연, 박은지, 배민경, 윤정현한국임상약학회 · 한국임상약학회지2011 · 제21권 제4호진행성 비소세포폐암의 표적치료 및 맞춤항암치료윤탁대한내과학회 · 대한내과학회지2009 · 제77권 제1호The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer김동완, 김범석, 김영주, 김태민, 이세훈, 이준구, 허대석대한암학회 · Cancer Research and Treatment2015 · 제47권 제2호비소세포폐암 환자의 표적 치료강두영, 길현일, 김수정, 남희림, 이윤규, 이현주, 함수연대한내과학회 · 대한내과학회지2024 · 제99권 제2호국내 폐암환자 전수 자료를 활용한 진행성 비소세포폐암 환자에서 EGFR 유전자변이에 따른 일차약으로서 개별맞춤형치료의 비용효과성 평가임은아, 최상은한국보건경제정책학회 · 보건경제와 정책연구2018 · 제24권 제2호국내 위암 환자에게 투여되는 항암제 처방 양상 및 의료비용 분석: Ramucirumab 급여 전후 비교 중심으로신주영, 정보란한국보건의료기술평가학회 · 보건의료기술평가2022 · 제10권 제2호

이 간행물의 다른 논문 (11건)

Pharmacokinetics of Once-Daily Amikacin in Korean Adult Patients지은희, 김혜경, 오정미, 안보숙pp. 208-214Effects of Amlodipine on the pharmacokinetics of Repaglinide최동현, 최준식pp. 215-223건강한 한국인 피험자에서 Entecavir 1 mg 제제의 약동학적 특성 평가전지영, 한수미, 임용진, 황민호, 채수완, 임성혁, 김윤정, 김민걸pp. 224-227Frequency of Clostridium difficile-associated Diarrhea and Relevant Medical Treatment in a Tertiary Care Hospital in Korea강혜경pp. 228-236의약품 부작용의 심각도 조사 비교분석이의경, 이진이, 허지행, 하지혜, 박미혜, 박세영pp. 237-242
원문 보기